Piper Sandler reiterates Overweight on Abbott Laboratories
Piper Sandler analyst Adam Maeder has reaffirmed an Overweight rating on Abbott Laboratories, maintaining a price target of $115.
*this image is generated using AI for illustrative purposes only.
Piper Sandler analyst Adam Maeder has reiterated an Overweight rating on Abbott Laboratories, maintaining a price target of $115. The rating affirmation reflects the firm's continued confidence in the healthcare company's stock performance.
Analyst Rating and Price Target
Piper Sandler's stance on Abbott Laboratories remains unchanged following the review. The $115 price target provides a reference point for investors regarding the stock's potential valuation.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| Piper Sandler | Adam Maeder | Overweight | $115 |
What specific catalysts does Piper Sandler expect to drive Abbott Laboratories toward the $115 price target?
How might Abbott's performance in its medical device and diagnostics segments influence future earnings growth?
What are the potential risks or challenges that could hinder Abbott from achieving the projected valuation?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
